Lupin has dipped 7% to Rs 830 after reporting 43% year-on-year (yoy) jump in its consolidated net profit at Rs 401 crore for quarter ended June 30, 2013 (Q1 FY14), mainly due to higher other income. The pharmaceutical company had profit of Rs 280 crore in year ago quarter.
Total income from operations grew 10% to Rs 2,476 crore for the quarter against Rs 2,254 crore in the corresponding quarter of previous fiscal.
Analyst on an average had expected net profit of Rs 383 crore and net sales of Rs 2,713 crore for the quarter.
The company’s other income has surged by over four-fold at Rs 101 crore during the recently concluded quarter. The company had other income of Rs 23.56 crore in a year ago quarter.
EBITDA margin expanded to 28.5% in Q1 FY14 as against 21.7% in Q1FY13, Lupin said in statement.
The stock opened at Rs 894 and touched low of Rs 822 on NSE. A combined 1.73 combined million shares changed hands on the counter so far on NSE and BSE.
Total income from operations grew 10% to Rs 2,476 crore for the quarter against Rs 2,254 crore in the corresponding quarter of previous fiscal.
Analyst on an average had expected net profit of Rs 383 crore and net sales of Rs 2,713 crore for the quarter.
The company’s other income has surged by over four-fold at Rs 101 crore during the recently concluded quarter. The company had other income of Rs 23.56 crore in a year ago quarter.
EBITDA margin expanded to 28.5% in Q1 FY14 as against 21.7% in Q1FY13, Lupin said in statement.
The stock opened at Rs 894 and touched low of Rs 822 on NSE. A combined 1.73 combined million shares changed hands on the counter so far on NSE and BSE.